Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...